Abstract：Objective To investigate the prevalence and influencing factors of hepatitis C virus (HCV) infection among drug users in Baoshan District, Shanghai Municipality, so as to provide insights into strengthening HCV intervention among drug users. Methods Drug users under community management in Baoshan District from 2017 to 2023 were recruited. Demographic information, drug use behaviors, sexual behaviors and receipt of intervention service were collected through questionnaire surveys. Blood samples were collected for HCV antibody testing, and the prevalence of anti-HCV antibody was analyzed. Factors affecting the prevalence of anti-HCV antibody among drug users were analyzed using a multivariable logistic regression model. Results A total of 2 801 drug users were surveyed, including 2 233 males (79.72%) and 568 females (20.28%). The majority of drug users were aged 40 to <60 years (1 663 drug users, 59.37%). The prevalence of anti-HCV antibody was 28.35%, showing an overall upward trend from 2017 to 2023 (P<0.05). Multivariable logistic regression analysis showed that females (OR=1.468, 95%CI: 1.169-1.844), 40 years and over (40 to <50 years, OR=2.441, 95%CI: 1.838-3.242; 50 to <60 years, OR=2.377, 95%CI: 1.787-3.161; 60 to 97 years, OR=1.637, 95%CI: 1.163-2.304), using traditional drugs (OR=2.488, 95%CI: 1.967-3.147) or mixed drugs (OR=2.950, 95%CI: 1.974-4.409), having injected drugs (not share needles, OR=3.649, 95%CI: 2.849-4.673; share needles, OR=3.532, 95%CI: 1.851-6.738) and never using condoms during sexual contacts with spouses/cohabitants in the past year (OR=1.975, 95%CI: 1.354-2.879) were associated with a higher prevalence of anti-HCV antibody; the educational level of high school/technical secondary school (OR=0.483, 95%CI: 0.280-0.835) or college and above (OR=0.280, 95%CI: 0.129-0.608) was associated with a lower prevalence of anti-HCV antibody. Conclusions The prevalence of anti-HCV antibody among drug users in Baoshan District showed an upward trend from 2017 to 2023. Gender, age, educational level, type of drugs, history of drug injection and never using condoms during sexual contacts with spouses/cohabitants were influencing factors for prevalence of anti-HCV antibody among drug users.
陈剑双, 朱礼明, 乐博昕, 王成义, 刘效峰, 何凡. 宝山区吸毒人群丙型肝炎病毒感染状况调查[J]. 预防医学, 2025, 37(2): 168-172.
CHEN Jianshuang, ZHU Liming, LE Boxin, WANG Chengyi, LIU Xiaofeng, HE Fan. Hepatitis C virus infection status among drug users in Baoshan District. Preventive Medicine, 2025, 37(2): 168-172.
[1] CUI F,BLACH S,MANZENGO M C,et al.Global reporting of progress towards elimination of hepatitis B and hepatitis C[J].Lancet Gastroenterol Hepatol,2023,8(4):332-342. [2] 白峻竹,游姝萌,张馨,等.2006—2020年中国丙型病毒性肝炎发病趋势及年龄-时期-队列分析[J].现代预防医学,2024,51(14):2497-2500. BAI J Z,YOU S M,ZHANG X,et al.Incidence trends and age-period-cohort analyses of hepatitis C in China,2006-2020[J].Mod Prev Med,2024,51(14):2497-2500.(in Chinese) [3] 龚韩湘,吴泽墉,伍宝玲,等.我国吸毒人群丙型肝炎病毒感染情况的系统评价[J].中国慢性病预防与控制,2017,25(8):625-628. GONG H X,WU Z Y,WU B L,et al.Hepatitis C virus infection among drug users in china:a systematic review[J].Chin J Prev Contr Chron Dis,2017,25(8):625-628.(in Chinese) [4] 甄华. 2012—2021年云南省边境县(市)血源及性传播疾病时空分布特征分析[D].长春:吉林大学,2024. ZHEN H.Analysis of spatiotemporal distribution characteristics of sexually transmitted and blood-borne infections in border area of Yunnan Province from 2012 to 2021[D].Changchun:Jilin University,2024.(in Chinese) [5] 中国疾病预防控制中心性病艾滋病预防控制中心.全国艾滋病哨点监测实施方案操作手册[Z].2017. The STD/AIDS Prevention and Control Center,Chinese Center for Disease Control and Prevention.Operation Manual for the Implementation Plan of National AIDS Sentinel Surveillance[Z].2017.(in Chinese) [6] 王宇,邢文革,刘中夫,等.丙型肝炎病毒感染的实验室检测方法及策略[J].临床肝胆病杂志,2024,40(4):672-678. WANG Y,XING W G,LIU Z F,et al.Advances in laboratory testing methods and strategies for hepatitis C virus infection[J].J Clin Hepatol,2024,40(4):672-678.(in Chinese) [7] 秦其荣,项可霞,高媛,等.马鞍山市2016—2018年吸毒人群艾滋病哨点监测结果分析[J].中国公共卫生,2021,37(8):1209-1213. QIN Q R,XIANG K X,GAO Y,et al.Prevalence of HIV infection and sexually transmitted diseases and their associates among drug users in Ma'anshan City,2016-2018:sentinel surveillance data analysis[J].Chin J Public Health,2021,37(8):1209-1213.(in Chinese) [8] 葛琳,李东民,李培龙,等.2010—2015年中国艾滋病哨点监测人群HIV、梅毒和HCV感染状况分析[J].疾病监测,2017,32(2):111-117. GE L,LI D M,LI P L,et al.Population specific sentinel surveillance for HIV infection, syphilis and HCV infection in China, during 2010-2015[J].Dis Surveill,2017,32(2):111-117.(in Chinese) [9] 吴振强,刘效峰,王娜,等.上海市宝山区2010—2016年吸毒人群HIV、丙肝和梅毒感染情况及影响因素分析[J].上海预防医学,2018,30(3):223-228. WU Z Q,LIU X F,WANG N,et al.Seroprevalence of human immunodeficiency virus,hepatitis C virus,and syphilis infection and their influencing factors among drug users in Baoshan District of Shanghai from 2010 to 2016[J].Shanghai J Prev Med,2018,30(3):223-228.(in Chinese) [10] 刘迎男,杨景元,李慧,等.内蒙古自治区吸毒人群丙型肝炎和梅毒感染分析[J].预防医学,2022,34(11):1125-1131. LIU Y N,YANG J Y,LI H,et al.Prevalence of hepatitis C and syphilis infections among drug users in Inner Mongolia Autonomous Region[J].China Prev Med J,2022,34(11):1125-1131.(in Chinese) [11] 李文军,李慧,杨景元,等.2008—2022年赤峰市丙型病毒性肝炎发病的年龄、时期、队列趋势分析[J].预防医学,2024,36(6):514-517. LI W J,LI H,YANG J Y,et al.Trends in age-,period- and cohort-specific incidence of hepatitis C in Chifeng City from 2008 to 2022[J].China Prev Med J,2024,36(6):514-517.(in Chinese) [12] 王娜,刘效峰,施大庆,等.上海市734例强制戒毒人员丙型病毒性肝炎感染影响因素和基因分型研究[J].中华疾病控制杂志,2018,22(4):330-334. WANG N,LIU X F,SHI D Q,et al.Study on influencing factors and genotypes of hepatitis C virus infection among 734 drug users in Shanghai compulsory detoxification center[J].Chin J Dis Control Prev,2018,22(4):330-334.(in Chinese) [13] 杨跃诚,张韵秋,叶润华,等.2011—2019年德宏傣族景颇族自治州吸毒人员HCV新发感染率及其影响因素[J].中国艾滋病性病,2022,28(7):801-805. YANG Y C,ZHANG Y Q,YE R H,et al.The incidence and risk factors of HCV infection among drug users in Dehong Dai and Jingpo Autonomous Prefectures,2011-2019[J].Chin J AIDS STD,2022,28(7):801-805.(in Chinese) [14] ARTENIE A,STONE J,FRASER H,et al.Incidence of HIV and hepatitis C virus among people who inject drugs,and associations with age and sex or gender: a global systematic review and meta-analysis[J].Lancet Gastroenterol Hepatol,2023,8(6):533-552.
